Is compounded semaglutide legal?

What the federal framework actually does

Sections 503A and 503B describe conditions under which certain compounded drugs qualify for exemptions from specified provisions that apply to conventionally manufactured drugs. FDA’s comparison makes clear that these exemptions depend on meeting the conditions; the section number is not a blanket authorization for every product a business sells. Other applicable law remains relevant. This guide summarizes the agency’s framework and does not provide a legal opinion on a particular provider, pharmacy or prescription. [3][2]

The question is therefore more specific than whether compounding exists in law. It asks who prepares the product, which pathway applies, what the prescription requires, which ingredients are used and whether the applicable restrictions are met. A telehealth company can arrange clinical care while another entity compounds the medicine. The company’s state coverage, subscription terms and pharmacy partner list do not independently answer those product-specific questions. [4]

503A: an individual prescription and limits on copies

FDA’s April 2026 policy reminder describes 503A compounding for an individual patient based on a prescription. It also highlights the restriction on regularly or in inordinate amounts compounding products that are essentially copies of commercially available drugs. The same notice explains a prescriber-documented change that produces a significant difference for an identified patient. That is a prescription-specific condition, not permission inferred from a cheaper price or a general customization slogan. [1]

Ask the prescribing service and pharmacy how the proposed preparation is identified and how the applicable requirements are addressed. A directory cannot establish the documented clinical basis or inspect the pharmacy’s operation from an enrollment page. Describing a business as a 503A pharmacy tells the reader about a regulatory category, but it does not by itself show that every semaglutide preparation dispensed there qualifies for the exemptions. [2][4]

503B: bulk-substance eligibility is a separate constraint

FDA’s current reminder says outsourcing facilities are restricted from using bulk drug substances unless the substance is on the applicable 503B list or the compounded drug is on the shortage list at the relevant stages. It states that semaglutide and tirzepatide are not currently on either list. An outsourcing facility’s registration does not put an ingredient onto the bulks list or create a new shortage exception. [1][5]

FDA also issued an April 2026 proposal to exclude several GLP-1 substances from the 503B bulks list. That source describes a proposal and comment process; we do not convert it into an independently verified final decision. The operative current point for this guide comes from the agency’s policy reminder and published list. A proposal, registered-facility entry and approved finished drug are different records. [6][5]

Why the shortage-era explanation is no longer enough

FDA determined the semaglutide injection shortage resolved on February 21, 2025. Its updates describe the subsequent enforcement-discretion periods and court-related chronology. Those dated arrangements should not be quoted as if their original temporary window remains available in October 2026. An article or advertisement based on shortage status needs the current status and applicable pathway checked separately. [1]

A difficulty locating a particular product at one pharmacy is not automatically a return to the national shortage-list category. FDA’s shortage guidance explains the distinction between listed shortages and other availability problems. Local fulfillment questions should go to the pharmacy and care team. They do not by themselves establish that routine compounded copies now qualify under a national shortage exception. [7][8]

Ingredients and add-ins do not remove the other requirements

FDA identifies semaglutide sodium and acetate as different active ingredients from those in approved drugs and says it is not aware of a lawful basis for their use in compounding. A seller’s general semaglutide label is therefore insufficient to identify the preparation. Ask the pharmacist for the actual ingredient description rather than assuming a familiar name authenticates a product or establishes the applicable legal conditions. [9]

The April policy reminder also discusses added ingredients, including a semaglutide-and-B12 example, in its explanation of essentially-copy restrictions. An additive is not automatically a legal escape from that framework. The relevant prescription-specific documentation and other conditions still matter. Our additive guide explains the labeling distinction without claiming that a particular vitamin or amino acid creates an approved or compliant substitute for a branded product. [1]

What a patient can verify without becoming the legal reviewer

Identify the prescribing organization and actual dispensing pharmacy, verify the pharmacy through the relevant official licensing channel, and ask the responsible parties about the proposed preparation. FDA BeSafeRx supplies online-pharmacy checks. Keep the pharmacy’s legal name distinct from a telehealth storefront so a product question reaches the entity that fills it. These checks establish useful facts about the service chain; they are not a private certification of every statutory condition. [10]

If a provider’s answer is only that its pharmacy is licensed or that semaglutide is cheaper when compounded, the legal-status question remains unanswered. Seek the explanation from the prescriber and pharmacy before treating a headline as authorization. The directory lists dated source-backed offerings and their limitations. It does not tell a patient to select compounded care or adjudicate whether an individual prescription lawfully qualifies for an exemption. [4][1]

Federal compounding conditions and state licensing are separate

A state pharmacy license is an important identity and authorization check, but it is not an answer to every federal condition for the preparation. Conversely, a company explaining a federal compounding pathway has not supplied proof of the relevant pharmacy’s state license. Keep the checks separate and match each claim to the official record or responsible organization. FDA describes overlapping state and federal oversight rather than a single badge that establishes approval, lawful copying, ingredient eligibility and fulfillment for every patient. [4][2]